Related Experiment Video
Updated: Jun 26, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Angiosarcoma in a soft tissue sarcoma cohort: real-world patterns and outcomes
Kübra Canaslan1, Özge Yetginoğlu1, Hasan Oğuz Çetinayak2
1Department of Medical Oncology, Dokuz Eylül University, İzmir, Türkiye.
Frontiers in Oncology
|June 25, 2026
Summary
Angiosarcoma is a rare cancer. This study found it often presents at an advanced stage, with poor survival outcomes even with current treatments for soft tissue sarcoma.
Area of Science:
- Oncology
- Sarcoma Research
- Vascular Neoplasms
Background:
- Angiosarcoma is a rare and aggressive vascular sarcoma.
- Limited real-world data exists on its clinical presentation and outcomes.
- It exhibits heterogeneous clinical behavior.
Purpose of the Study:
- To analyze the clinical characteristics, treatment patterns, and survival outcomes of angiosarcoma patients.
- To evaluate the real-world effectiveness of current therapies for angiosarcoma.
- To identify challenges in managing this rare sarcoma.
Main Methods:
- Retrospective review of adult soft tissue sarcoma cases at a single institution (January 2019-September 2025).
- Identification of pathologically confirmed angiosarcoma cases.
- Extraction of clinical, pathological, treatment, and survival data from electronic medical records.
- Descriptive statistics and Kaplan-Meier methods for survival analysis.
Main Results:
- Angiosarcoma accounted for 2.2% of soft tissue sarcoma cases (12/548).
- The majority (58.3%) were visceral, with a median age of 62 years.
- 75% of patients presented with metastatic or unresectable disease.
- First-line therapy (paclitaxel- or anthracycline-based) in advanced cases showed limited efficacy.
- Median overall survival was 9.5 months and median progression-free survival was 4.8 months.
Conclusions:
- Angiosarcoma is rare but often diagnosed at an advanced stage.
- Current therapies provide limited survival benefits, with poor overall survival and progression-free survival.
- Multi-center studies are needed to improve risk stratification and treatment strategies.
Related Concept Videos
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...